Herausgegeben:Cagle, Philip T.; Allen, Timothy Craig; Beasley, Mary Beth; Chirieac, Lucian R.; Dacic, Sanja; Borczuk, Alain C.; Kerr, Keith M; Sholl, Lynette M.; Portier, Bryce; Bernicker, Eric H.
Herausgegeben:Cagle, Philip T.; Allen, Timothy Craig; Beasley, Mary Beth; Chirieac, Lucian R.; Dacic, Sanja; Borczuk, Alain C.; Kerr, Keith M; Sholl, Lynette M.; Portier, Bryce; Bernicker, Eric H.
This new edition provides the latest information and insights into the molecular basis for lung cancer. Since the publication of the previous edition of this volume, dramatic changes have occurred with the classification of lung cancer, biomarker testing, and molecular therapy. The book covers these changes, providing updates and new insights on the background of lung cancer, testing methods, and the molecular pathology of specific cell types, including adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and precursor and preinvasive lesions. Authored by experts in the field,…mehr
This new edition provides the latest information and insights into the molecular basis for lung cancer. Since the publication of the previous edition of this volume, dramatic changes have occurred with the classification of lung cancer, biomarker testing, and molecular therapy. The book covers these changes, providing updates and new insights on the background of lung cancer, testing methods, and the molecular pathology of specific cell types, including adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and precursor and preinvasive lesions. Authored by experts in the field, Precision Molecular Pathology of Lung Cancer, Second Edition remains one of the few books that comprehensively covers the new molecular pathology of lung cancer and is a valuable resource for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, and thoracic radiologists.
Philip T. Cagle, MD Houston Methodist Hospital Department of Pathology & Genomic Medicine 6565 Fannin St Houston, TX 77030 Timothy C. Allen, MD The University of Texas Medical Branch Department of Pathology 301 University Boulevard Galveston, TX 77555 Mary Beth Beasley, MD Mount Sinai Hospital Department of Pathology 1468 Madison Avenue New York, NY 10029 Lucian R. Chirieac, MD Brigham And Women's Hospital Department of Pathology 75 Francis St. Boston, MA 02115 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center Department of Pathology 200 Lothrop St. Pittsburgh, PA 15213 Alain C. Borczuk, MD Weill Cornell University Medical Center Department of Pathology 1300 York Avenue Starr-1000A New York, NY 10065 Keith M. Kerr, MD Aberdeen University Medical School Aberdeen Royal Infirmary Department of Pathology Foresterhill Aberdeen, Scotland Lynette Sholl, MD Brigham And Women's Hospital Department of Pathology 75 Francis St Boston, MA 02115 Bryce Portier, MD Houston Methodist Hospital Department of Pathology & Genomic Medicine 6565 Fannin St Houston, TX 77030 Eric Bern icker, MD Houston Methodist Hospital Thoracic Medical Oncology 6445 Main St, Floor 21 Houston, TX 77030
Inhaltsangabe
I. Background.- 1. Precision Medicine of Lung Cancer: Introduction.- 2. Lung Cancer Epidemiology and Demographics.- 3. Genetic Susceptibility to Lung Cancer.- 4. Lung Cancer Stem Cells.- 5. The 2015 World Health Organization Classification of Lung Cancer: Overview.- II. Testing Methods.- 6. Preanalytic considerations.- 7. Mutation testing of lung cancer biomarkers.- 8. Translocation testing of lung cancer biomarkers.- 9. Immunohistochemistry of lung cancer biomarkers.- 10. Next Generation and Third Generation Sequencing of lung cancer biomarkers.- III. Molecular Pathology of Specific Cell Types.- 11. Mutations as Predictive Biomarkers for Adenocarcinoma.- 12. Translocations as predictive Biomarkers for Adenocarcinoma.- 13. Predictive Biomarkers for Squamous Cell Carcinoma.- 14. Molecular Pathology of Small Cell Carcinoma.- 15. Molecular Pathology of Uncommon Carcinomas.- 16. Molecular Pathology of Lung Cancer Metastases.- 17. Molecular Pathology of Precursor and Preinvasive Lesions.- IV. General and Emerging Fields in Molecular Pathology of Lung Cancer.- 18. Prognostic biomarkers in lung cancer.- 19. Biomarkers and Differing Therapy Modalities.- 20. Immuno-oncology of Lung Cancer.- 21. Liquid Biopsy.
I. Background.- 1. Precision Medicine of Lung Cancer: Introduction.- 2. Lung Cancer Epidemiology and Demographics.- 3. Genetic Susceptibility to Lung Cancer.- 4. Lung Cancer Stem Cells.- 5. The 2015 World Health Organization Classification of Lung Cancer: Overview.- II. Testing Methods.- 6. Preanalytic considerations.- 7. Mutation testing of lung cancer biomarkers.- 8. Translocation testing of lung cancer biomarkers.- 9. Immunohistochemistry of lung cancer biomarkers.- 10. Next Generation and Third Generation Sequencing of lung cancer biomarkers.- III. Molecular Pathology of Specific Cell Types.- 11. Mutations as Predictive Biomarkers for Adenocarcinoma.- 12. Translocations as predictive Biomarkers for Adenocarcinoma.- 13. Predictive Biomarkers for Squamous Cell Carcinoma.- 14. Molecular Pathology of Small Cell Carcinoma.- 15. Molecular Pathology of Uncommon Carcinomas.- 16. Molecular Pathology of Lung Cancer Metastases.- 17. Molecular Pathology of Precursor and Preinvasive Lesions.- IV. General and Emerging Fields in Molecular Pathology of Lung Cancer.- 18. Prognostic biomarkers in lung cancer.- 19. Biomarkers and Differing Therapy Modalities.- 20. Immuno-oncology of Lung Cancer.- 21. Liquid Biopsy.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826